Speed to Market was key to Intercept Pharmaceuticals’ Ocaliva Launch

[Editor's note: This is an updated version of this story, which was initially published online July 19, 2016]

U.S. patients suffering with primary biliary cholangitis now can treat the chronic liver disease with Ocaliva™ (obeticholic acid), developed as a result of a partnership between biopharmaceutical firm Intercept Pharmaceuticals, Inc. and the Almac Group, a global contract development and manufacturing organization.